Terumo Medical Corp

Terumo Medical Corp's Terumo Interventional Systems Division manufactures and sells cardiovascular and interventional medical devices—vascular implants, stents, grafts, embolization coils, catheters, and endovascular repair systems—to the federal government as a prime contractor, competing under full and open competition with no SBA set-aside designations. The company is a for-profit manufacturer headquartered in Somerset, New Jersey, with place of performance at multiple U.S. locations including Somerset, Irvine, Fresno, and Miami.

Terumo's federal footprint is overwhelmingly Veterans Affairs–centered. The company holds a $138.09 million Federal Supply Schedule contract (Medical Equipment and Supplies FSS-65-II-A) awarded May 15, 2021, extending through May 14, 2026, which anchors 428 task orders carrying $24 million in combined potential value. The top customer by dollar magnitude is Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12, with 17 awards worth $284.5 million in combined potential value—a concentration figure driven largely by the parent FSS contract. By award count, DLA Troop Support Medical leads with 125 awards at $110 thousand combined potential value, followed by VA VISN 8 (89 awards, $1.5 million), VA VISN 1 (86 awards, $1.2 million), VA VISN 2 (73 awards, $771 thousand), and VA VISN 17 (68 awards, $1 million). These five customers account for 44% of awards. Secondary customers include the Army Medical Command (26 awards, $8.2 million), VA VISN 19 (26 awards, $5.2 million), and the Navy Bureau of Medicine and Surgery (34 awards, $1.3 million). The divergence between the two rankings—VISN 12's dominance by dollars versus DLA Troop Support's dominance by order count—reflects the parent FSS vehicle's institutional purchasing power versus transactional order volume.

Recent award activity shows contraction. Terumo received 61 awards in 2022, declining to 31 in 2023, 28 in 2024, 26 in 2025, and 24 through September 2026. The combined potential value across all 1,008 prime and sub awards since 2010 totals $323.8 million, with only $13.7 million obligated to date (4% utilization). Seven awards totaling $191 thousand in combined potential value reach completion within the next twenty-four months, presenting limited recompete exposure. The vendor's prime footprint is 99% of all awards; subcontract activity is minimal, limited to indirect supplies delivered through Cardinal Health 200, LLC for medical device components. Place of performance spans multiple VA medical center locations nationwide, with administrative sourcing from Somerset, New Jersey, and operational facilities in California, Florida, and elsewhere.

Terumo competes solely in the medical device-manufacturing space—primarily NAICS 333994 (Surgical and Medical Instrument Manufacturing) and 339113 (Surgical Appliance and Supplies Manufacturing)—with PSC concentration at 965 awards in the Medical And Surgical Instruments, Equipment, And Supplies category. Individual order values typically range from $11,000 to $75,000, with firm fixed pricing and streamlined procurement mechanics characteristic of supply-schedule and blanket-purchase-agreement vehicles. The company maintains several BPAs with individual VISNs, including a $459,895 consignment BPA with VISN 19 for AZUR embolization coils (awarded May 15, 2026, through May 14, 2031), and smaller single-award BPAs with VISN 12 ($18,907), VISN 1 ($1), and VISN 19 ($378,361). These vehicle holdings and the scale of the parent FSS contract position Terumo as the incumbant supplier of proprietary interventional cardiovascular devices to VA medical facilities, with procurement justified on patient safety and clinical-necessity grounds requiring immediate availability of full product ranges during surgical procedures.